AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — FY2011 Earnings Presentation

16 slides from AMAG Pharmaceuticals's earnings presentation, Mar 5, 2012

  1. Slide 1: 2011 Financial Results Call March 5, 2012

    2011 Financial Results Call March 5, 2012

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: our sta

  3. Slide 3: Agenda

    Agenda 2 Topic Speaker Overview Frank Thomas, COO and interim CEO Commercial Progress John Tucker, VP Commercial Operations Growth Opportunities, Financial Overview and Closing Remarks Frank Thomas Q&A All

  4. Slide 4: AMAG: A Review of 2011

    3Q11: FDA harmonizes most IV iron labels to contain 30-minute observation periods post-dosing Proposed merger with Allos did not receive the required votes by AMAG stockholders 1Q11: CMS implements bundle for dialysis patients; erodes significant portion of AMAG revenue AMAG sales force realigned to

  5. Slide 5: Leveraging Core Assets to Create Long-term Stockholder Value

    Leveraging Core Assets to Create Long-term Stockholder Value AMAG’s Key Assets Strong balance sheet, with approximately $230 million in cash and no debt Feraheme, an approved product in the U.S. and Canada, that generates more than $50 million a year in U.S. revenues Focused U.S. commercial footprin

  6. Slide 6: Commercial Progress

    > Commercial Progress a

  7. Slide 7: Feraheme — Strong Momentum in Non-Dialysis CKD Market

    7 Feraheme — Strong Momentum in Non-Dialysis CKD Market -Historic results based on IMS Monthly Data, IMS Weekly Data and Wholesaler Shipment Data. Feraheme Grams ~40% Growth in Feraheme Provider Demand from 2010 - 2011 >15% Growth in Feraheme Provider Demand Estimated from 2011 - 2012

  8. Slide 8: Feraheme Non-Dialysis CKD Provider Demand

    Feraheme Non-Dialysis CKD Provider Demand 8 Feraheme Grams Source: IMS monthly data and wholesaler shipment data for 1/29/12 – 2/25/12.

  9. Slide 9: Non-Dialysis IV Iron Market: Major Sites of Administration/Influence for CKD Patients

    Non-Dialysis IV Iron Market: 3 Major Sites of Administration/Influence for CKD Patients Multiple sites of care Formulary drives access IV Iron Grams in Segment: ~513,0001 Estimated % of Total IV Use: ~65%1 Limited IV iron use Generally more conservative IV Iron Grams in Segment: ~24,0001 Estimated %

  10. Slide 10: Critical Commercial Success Factors in 2012

    Critical Commercial Success Factors in 2012 Implementing targeted account call plan for sales representatives focused on: Driving share in hospitals with large infusion clinics and outpatient formularies where large numbers of CKD patients are treated utilizing contracting and physician relationship

  11. Slide 11: Feraheme Growth Opportunities and Financial Overview

    Feraheme Growth Opportunities and Financial Overview 11

  12. Slide 12: Feraheme Provides Solid Foundation for Growth

    Feraheme Provides Solid Foundation for Growth 12 Growth Initiatives US CKD Market Current market share of non-dialysis market has grown to 12% Market share growth achieved in 2011 Hem/Onc - 20% to 24% Hospital - 6% to 7% Nephrology share exited 2011 at 44% Segment specific initiatives should drive i

  13. Slide 13: Financial Highlights

    Financial Highlights Year Ended ($ in millions, except per share ) Q4-2011 Q4-2010 2011 2010 Total Revenues $14.9 $17.2 $61.2 $66.2 Net Product Revenues 12.9 15.3 52.8* 60.0 Cost of Product Sales 2.7 2.4 10.5 7.6 R&D Expenses 13.0 13.3 58.1 54.5 SG&A Expenses 15.2 19.5 68.9 84.9 Net Loss (18.6) (19.

  14. Slide 14: Strong Financial Profile: 2012 Financial Outlook

    Strong Financial Profile 14 GAAP Revenue Operating Expenses (excluding COGS) ($ in millions) ($ in millions) $53 – $57 million in Feraheme net product revenue >15% growth in grams $33 million of cash milestones received COGS assumed to be 14-18% of net product sales $90 – $95 million in total operat

  15. Slide 15: Multiple 2012 Milestones Provide Growth Opportunities

    Multiple 2012 Milestones Provide Growth Opportunities Clinical and regulatory Complete enrollment of broad IDA phase 3 registration program Regulatory decisions in international markets on CKD filings Present/publish IDA program data Submit sNDA in US for broad IDA indication Commercial and business

  16. Slide 16: Q&A

    Q&A 16 INVESTOR RELATIONS CONTACT: 617-498-3303

AMAG Pharmaceuticals — FY2011 Earnings Presentation on 6ix